Korro Bio Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones

Reuters03-20

<a href="https://laohu8.com/S/KRRO">Korro Bio</a> Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones

Korro outlined plans to develop RNA-editing medicines that modify RNA without permanently changing DNA, with a focus on rare and prevalent diseases.
A regulatory filing for lead program KRRO-121 in hyperammonemia is anticipated in H2 2026.
A development candidate is expected in Q2 2026 for a GalNAc-conjugated construct targeting alpha-1 antitrypsin deficiency, and another GalNAc-conjugated liver asset is expected to reach development-candidate stage in H2 2026.
Cash, cash equivalents and marketable securities were reported at USD 85.2 million as of December 31, 2025.
The presentation described KRRO-121 as a GalNAc-conjugated oligonucleotide designed for liver-specific RNA editing of glutamine synthetase to enhance ammonia clearance capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620822229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 00:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620822229","market":"nz","top_or_hot":-1,"title":"Korro Bio Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Korro outlined plans to develop RNA-editing medicines that modify RNA without permanently changing DNA, with a focus on rare and prevalent diseases.\n        </li>\n<li>\n          A regulatory filing for lead program KRRO-121 in hyperammonemia is anticipated in H2 2026.\n        </li>\n<li>\n          A development candidate is expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 for a GalNAc-conjugated construct targeting alpha-1 antitrypsin deficiency, and another GalNAc-conjugated liver asset is expected to reach development-candidate stage in H2 2026.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities were reported at USD 85.2 million as of December 31, 2025.\n        </li>\n<li>\n          The presentation described KRRO-121 as a GalNAc-conjugated oligonucleotide designed for liver-specific RNA editing of glutamine synthetase to enhance ammonia clearance capacity.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 00:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Korro outlined plans to develop RNA-editing medicines that modify RNA without permanently changing DNA, with a focus on rare and prevalent diseases.\n        </li>\n<li>\n          A regulatory filing for lead program KRRO-121 in hyperammonemia is anticipated in H2 2026.\n        </li>\n<li>\n          A development candidate is expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 for a GalNAc-conjugated construct targeting alpha-1 antitrypsin deficiency, and another GalNAc-conjugated liver asset is expected to reach development-candidate stage in H2 2026.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities were reported at USD 85.2 million as of December 31, 2025.\n        </li>\n<li>\n          The presentation described KRRO-121 as a GalNAc-conjugated oligonucleotide designed for liver-specific RNA editing of glutamine synthetase to enhance ammonia clearance capacity.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRRO","symbol_name":"Korro Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL16GynJ:1","article_id":"2620822229","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620822229","pubTimestamp":1773936368,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Korro outlined plans to develop RNA-editing medicines that modify RNA without permanently changing DNA, with a focus on rare and prevalent diseases.A development candidate is expected in Q2 2026 for a GalNAc-conjugated construct targeting alpha-1 antitrypsin deficiency, and another GalNAc-conjugated liver asset is expected to reach development-candidate stage in H2 2026.Cash, cash equivalents and marketable securities were reported at USD 85.2 million as of December 31, 2025.The presentation described KRRO-121 as a GalNAc-conjugated oligonucleotide designed for liver-specific RNA editing of glutamine synthetase to enhance ammonia clearance capacity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRRO":"Korro Bio, Inc.","BK4139":"生物科技"},"translate_title":"Korro Bio Inc.发布有关RNA编辑基因药物和管道里程碑的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"Korro Bio Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones\n    \n\n\n          Korro outlined plans to develop RNA-editing medicines that modify RNA without permanently changing DNA, with a focus on rare and prevalent diseases.\n        \n\n          A regulatory filing for lead program KRRO-121 in hyperammonemia is anticipated in H2 2026.\n        \n\n          A development candidate is expected in Q2 2026 for a GalNAc-conjugated construct targeting alpha-1 antitrypsin deficiency, and another GalNAc-conjugated liver asset is expected to reach development-candidate stage in H2 2026.\n        \n\n          Cash, cash equivalents and marketable securities were reported at USD 85.2 million as of December 31, 2025.\n        \n\n          The presentation described KRRO-121 as a GalNAc-conjugated oligonucleotide designed for liver-specific RNA editing of glutamine synthetase to enhance ammonia clearance capacity.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620822229","isCrawlerRequest":true}